相关实验视频

Updated: Jan 10, 2026

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia

A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia

Published on: May 21, 2010

病理性ATAXIN-3聚合的Allosteric调制:通往脊髓小脑形性形症的途径 3型治疗方法

Alexandra Silva¹, Sara Duarte-Silva², Pedro M Martins¹

¹i3S -Institute for Research and Innovation in Health, Institute for Molecular and Cellular Biology (IBMC), Porto University, Porto, 4200-150, Portugal.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|November 27, 2025

概括

一种针对3型脊髓小脑动症 (SCA3) 的新疗法减少了有毒蛋白质聚合. 这种方法改善了SCA3在临床前模型中的运动功能和延迟疾病发作,为神经退行性疾病治疗提供了希望.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

3型脊髓小脑动症 (SCA3) 是一种致命的神经退行性疾病.
目前对SCA3的治疗方法缺乏疾病修饰能力.
ATAXIN-3 (Atx3) 蛋白的病理聚合是SCA3.3的一个关键特征.

研究的目的:

调查超分子针CLR01的潜力,以抑制Atx3的自我组装.
探索CLR01作为SCA3.3的治疗策略.
为了确定针对蛋白质误折叠障碍的新型全位.

主要方法:

生物化学试验用于研究CLR01与Atx3.3的结合.
在体外测试以评估Atx3粉样纤维的形成和二次核化.
使用SCA3细胞和动物模型 (C. elegans和小鼠) 的体内研究.

主要成果:

CLR01与Atx3约瑟芬域上的全位结合,减少聚合而不会影响酶活性.
治疗CLR01抑制了Atx3粉样纤维的形成和二次核化.
在SCA3模型中,CLR01逆转了突触损失,改善了运动功能,延迟了疾病发作,并减少了症状严重程度.

结论:

用CLR01准Atx3上的全位是SCA3.3的一个有希望的治疗策略.
通过异质调制抑制病态蛋白质自我组装为治疗蛋白质错折障碍提供了一条新的途径.
在SCA3和其他神经退行性疾病中,CLR01显示出疾病修饰的潜力.

关键词:

氨基化物氨基化物分子疗法是分子疗法.分子子分子子聚氨酸多重蛋白质胺的方法在临床前的模型中.蛋白质动力学蛋白质动力学

更多相关视频

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Published on: November 11, 2014

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

相关概念视频

Allosteric Regulation

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...